The real-world experience with nivolumab in previously treated patients with advanced non small cell lung cancer (NSCLC): A Galician Lung Cancer Group clinical practice.

M. C. Areses, R. Campelo, Jorge G. González,F. J. Afonso,M. Lázaro,B. Campos, C. Azpitarte,M. Amenedo,L. Santomé, D. Ron,G. Alonso-Jáudenes,F. Barón, R. Vilchez,J. Casal,N. Fernández, I. Carou, J. Mosquera,U. Anido, J. G. Mata,J. Fírvida

semanticscholar（2017）

引用 0|浏览0

暂无评分

摘要

e20564Background: Nivolumab, was the first checkpoint inhibitor to show a survival benefit in previously treated patients with advanced NSCLC in two randomized trials (CheckMate 017 and 057). Exper...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要